Hypercholesterolemia: all 1,267 studies

Page 3 of 13. Open to participants first (105), then studies with results posted, then the rest; newest registration first within each.

• Pharmacy Home Adherence Reporting and Monitoring Outcomes StudyCompletedNCT02306122Not applicableResults posted
• Open-label Extension (OLE) Study to Assess Safety and Efficacy of EvolocumabCompletedNCT02304484Phase 3Results posted
• Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and TaiwanCompletedNCT02289963Phase 3Results posted
• Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT02265952Phase 2Results posted
• A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary HypercholesterolemiaTerminatedNCT02260648Phase 3Results posted
• A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary HypercholesterolemiaTerminatedNCT02260635Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT02226198Phase 3Results posted
• Vascular Lifestyle-Intervention and Screening in PharmacyStatus unknownNCT02223793Not applicableResults posted
• Evaluation of ETC-1002 in Participants With Hypercholesterolemia and HypertensionCompletedNCT02178098Phase 2Results posted
• Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering TherapyCompletedNCT02173158Phase 3Results posted
• The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney DiseaseTerminatedNCT02133534Phase 4Results posted
• Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)CompletedNCT02107898Phase 3Results posted
• Safety Study of AEM-28 to Treat Refractory HypercholesterolemiaCompletedNCT02100839Phase 1/2Results posted
• Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese SubjectsCompletedNCT02055976Phase 2Results posted
• Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper ArmCompletedNCT02043301Phase 1Results posted
• Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)CompletedNCT02023879Phase 3Results posted
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial HypercholesterolemiaCompletedNCT01968980Phase 3Results posted
• Actual Use Trial of Atorvastatin Calcium 10 mgCompletedNCT01964326Phase 3Results posted
• Open Label Study of Long Term Safety Evaluation of AlirocumabCompletedNCT01954394Phase 3Results posted
• Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular RiskCompletedNCT01953328Phase 3Results posted
• Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol LevelsCompletedNCT01935674Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)CompletedNCT01926782Phase 3Results posted
• Genetically Guided Statin TherapyCompletedNCT01894230Not applicableResults posted
• A Study of LY3015014 in Participants With High CholesterolCompletedNCT01890967Phase 2Results posted
• One-Day Acceptance and Commitment Training Intervention in Primary Care PatientsCompletedNCT01879800Not applicableResults posted
• Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/PenCompletedNCT01879319Phase 3Results posted
• Gene Analysis and Treatment Optimization in Chinese Homozygous Familial HypercholesterolemiaCompletedNCT01878604Results posted
• Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/PenCompletedNCT01849497Phase 3Results posted
• Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated CholesterolCompletedNCT01817491Not applicableResults posted
• GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular UltrasoundCompletedNCT01813422Phase 3Results posted
• Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in JapanCompletedNCT01812707Phase 2Results posted
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated RiskCompletedNCT01764633Phase 3Results posted
• Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2CompletedNCT01763918Phase 3Results posted
• A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin IntoleranceCompletedNCT01751984Phase 2Results posted
• Cholesterol Medication Packaging StudyCompletedNCT01744977Not applicableResults posted
• Medication Adherence With Polyglot MeducationCompletedNCT01744392Not applicableResults posted
• Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)CompletedNCT01730053Phase 3Results posted
• Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)CompletedNCT01730040Phase 3Results posted
• Efficacy and Safety Study of Pitavastatin for HypercholesterolemiaCompletedNCT01710007Phase 3Results posted
• Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)CompletedNCT01709513Phase 3Results posted
• Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)CompletedNCT01709500Phase 3Results posted
• Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRSCompletedNCT01702987Not applicableResults posted
• A Study of LY3015014 in Healthy Participants With High CholesterolCompletedNCT01671085Phase 1Results posted
• A Study Comparing CoQ10 Levels While Taking 3 Different StatinsCompletedNCT01660191Phase 4Results posted
• A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese SubjectsCompletedNCT01652703Phase 2Results posted
• Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With HypercholesterolemiaCompletedNCT01644474Phase 3Results posted
• Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)CompletedNCT01644188Phase 3Results posted
• Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)CompletedNCT01644175Phase 3Results posted
• Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL DisordersCompletedNCT01624142Phase 2/3Results posted
• Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying TherapyCompletedNCT01623115Phase 3Results posted
• Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)CompletedNCT01617655Phase 3Results posted
• A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)CompletedNCT01611883Phase 4Results posted
• A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneCompletedNCT01604824Phase 2Results posted
• Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A StatinCompletedNCT01592240Phase 2Results posted
• Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor AbnormalitiesCompletedNCT01588496Phase 2/3Results posted
• A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)TerminatedNCT01583647Phase 1Results posted
• Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT01576484Phase 2Results posted
• Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) InhibitorCompletedNCT01556906Phase 2Results posted
• Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaCompletedNCT01551173Phase 4Results posted
• LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENtsCompletedNCT01544309Not applicableResults posted
• Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)CompletedNCT01524289Phase 3Results posted
• Durable Effect of PCSK9 Antibody CompARed wiTh placEbo StudyCompletedNCT01516879Phase 3Results posted
• Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)CompletedNCT01507831Phase 3Results posted
• A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein CholesterolCompletedNCT01475825Phase 3Results posted
• Open Label Study of Long Term Evaluation Against LDL-C TrialCompletedNCT01439880Phase 2Results posted
• A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With HypercholesterolemiaCompletedNCT01435382Phase 1Results posted
• Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed DyslipidemiaCompletedNCT01420549Phase 3Results posted
• A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)CompletedNCT01414192Results posted
• Effect of Beta-Glucan on Cholesterol LoweringCompletedNCT01408719Not applicableResults posted
• Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)CompletedNCT01381679Results posted
• Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder StudyCompletedNCT01375751Phase 2Results posted
• A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)CompletedNCT01370603Phase 3Results posted
• A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)CompletedNCT01370590Phase 3Results posted
• A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of StatinsCompletedNCT01350141Phase 2Results posted
• A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of StatinsCompletedNCT01342211Phase 2Results posted
• Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)TerminatedNCT01335997Phase 3Results posted
• A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)CompletedNCT01333436Not applicableResults posted
• A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)TerminatedNCT01294683Phase 3Results posted
• Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary HypercholesterolemiaCompletedNCT01288469Phase 2Results posted
• Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin TherapyCompletedNCT01288443Phase 2Results posted
• Tailored Communication to Reduce Cardiovascular RiskCompletedNCT01286311Not applicableResults posted
• Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)TerminatedNCT01274559Phase 3Results posted
• Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH HypercholesterolemiaCompletedNCT01266876Phase 2Results posted
• Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)CompletedNCT01245738Results posted
• Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With HypercholesterolemiaCompletedNCT01243151Phase 1Results posted
• Statins in Children With Type 1 Diabetes and HypercholesterolemiaCompletedNCT01236365Phase 3Results posted
• Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)TerminatedNCT01228019Results posted
• Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque RegressionCompletedNCT01212900Phase 4Results posted
• Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese PatientsCompletedNCT01190007Phase 4Results posted
• Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With AtorvastatinCompletedNCT01163851Phase 1Results posted
• MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)CompletedNCT01154036Phase 3Results posted
• Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)CompletedNCT01107743Results posted
• An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial HypercholesterolaemiaCompletedNCT01078675Phase 3Results posted
• Vytorin Reexamination Study (0653A-174)CompletedNCT01070966Results posted
• EZETROL® Re-examination Study (MK0653-175)(COMPLETED)CompletedNCT01070953Results posted
• Ezetimibe in Patients Hypo-responsive to StatinsTerminatedNCT00965055Phase 3Results posted
• Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT00943306Phase 3Results posted
• Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)CompletedNCT00941603Phase 2Results posted
• Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)CompletedNCT00935259Phase 1Results posted
• Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)CompletedNCT00932620Phase 4Results posted

← Hypercholesterolemia overview